Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on October 7, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on October 7, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 176 Common Stock at $542.73 ($95,521) on October 7, 2026; holds 333,767 after (Indirect).
- Open-market sale: disposed of 744 Common Stock at $543.76 ($404,557) on October 7, 2026; holds 333,023 after (Indirect).
- Open-market sale: disposed of 2,098 Common Stock at $544.82 ($1,143,035) on October 7, 2026; holds 330,925 after (Indirect).
- Open-market sale: disposed of 493 Common Stock at $545.85 ($269,104) on October 7, 2026; holds 330,432 after (Indirect).
- Open-market sale: disposed of 629 Common Stock at $546.94 ($344,028) on October 7, 2026; holds 329,803 after (Indirect).
- Open-market sale: disposed of 387 Common Stock at $548.18 ($212,144) on October 7, 2026; holds 329,416 after (Indirect).
- Open-market sale: disposed of 1,173 Common Stock at $549.13 ($644,130) on October 7, 2026; holds 328,243 after (Indirect).
- Open-market sale: disposed of 874 Common Stock at $550.14 ($480,819) on October 7, 2026; holds 327,369 after (Indirect).
- Open-market sale: disposed of 486 Common Stock at $551.09 ($267,832) on October 7, 2026; holds 326,883 after (Indirect).
- Open-market sale: disposed of 440 Common Stock at $552.29 ($243,010) on October 7, 2026; holds 326,443 after (Indirect).
- Open-market sale: disposed of 185 Common Stock at $553.70 ($102,435) on October 7, 2026; holds 326,258 after (Indirect).
- Open-market sale: disposed of 485 Common Stock at $554.51 ($268,939) on October 7, 2026; holds 325,773 after (Indirect).
- Open-market sale: disposed of 930 Common Stock at $555.77 ($516,869) on October 7, 2026; holds 324,843 after (Indirect).
- Open-market sale: disposed of 400 Common Stock at $556.48 ($222,594) on October 7, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on October 7, 2026; holds 280,910 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,215,015 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-07 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-10-07 | Open-market sale | Common Stock | 176 | $543 | $95.5K | 333,767 |
| 2026-10-07 | Open-market sale | Common Stock | 744 | $544 | $404.6K | 333,023 |
| 2026-10-07 | Open-market sale | Common Stock | 2,098 | $545 | $1.1M | 330,925 |
| 2026-10-07 | Open-market sale | Common Stock | 493 | $546 | $269.1K | 330,432 |
| 2026-10-07 | Open-market sale | Common Stock | 629 | $547 | $344.0K | 329,803 |
| 2026-10-07 | Open-market sale | Common Stock | 387 | $548 | $212.1K | 329,416 |
| 2026-10-07 | Open-market sale | Common Stock | 1,173 | $549 | $644.1K | 328,243 |
| 2026-10-07 | Open-market sale | Common Stock | 874 | $550 | $480.8K | 327,369 |
| 2026-10-07 | Open-market sale | Common Stock | 486 | $551 | $267.8K | 326,883 |
| 2026-10-07 | Open-market sale | Common Stock | 440 | $552 | $243.0K | 326,443 |
| 2026-10-07 | Open-market sale | Common Stock | 185 | $554 | $102.4K | 326,258 |
| 2026-10-07 | Open-market sale | Common Stock | 485 | $555 | $268.9K | 325,773 |
| 2026-10-07 | Open-market sale | Common Stock | 930 | $556 | $516.9K | 324,843 |
| 2026-10-07 | Open-market sale | Common Stock | 400 | $556 | $222.6K | 324,443 |
| 2026-10-07 | Option exercise/conversion | Stock Option | 9,500 | — | — | 280,910 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-07 | Option exercise/conversion (9,500 shares) |
| 2026-10-07 | Open-market sale (176 shares) |
| 2026-10-07 | Open-market sale (744 shares) |
| 2026-10-07 | Open-market sale (2,098 shares) |
| 2026-10-07 | Open-market sale (493 shares) |
| 2026-10-07 | Open-market sale (629 shares) |
| 2026-10-07 | Open-market sale (387 shares) |
| 2026-10-07 | Open-market sale (1,173 shares) |
| 2026-10-07 | Open-market sale (874 shares) |
| 2026-10-07 | Open-market sale (486 shares) |
| 2026-10-07 | Open-market sale (440 shares) |
| 2026-10-07 | Open-market sale (185 shares) |
| 2026-10-07 | Open-market sale (485 shares) |
| 2026-10-07 | Open-market sale (930 shares) |
| 2026-10-07 | Open-market sale (400 shares) |
| 2026-10-07 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.